Kidney Cancer triplet slows progression in advanced disease when compared to immunotherapy combo (nivolumab + ipilimumab).
Hello. This is dr Tony sherry from the Dana Farber Cancer Institute. We really it was an honor to present during the plenary the presidential session at the 2022 asthma, european Society of Medical Oncology meeting in paris. The first result from cosmic 313 cosmic 313 is a phase three trial for the first time using a modern control, a modern doublet control uh here of and asking the question whether in metastatic kidney cancer adding the drug caboose Anthony would lead to improved outcomes and positive results. The primary endpoint of the study was to show an improvement in when we and what we call progression free survival. So this is in a way the time patient stay on therapy without their tumor growing. The combination of caboose internet vilma and mama met the primary and Point of progression free survival over the two drug of naval a mat and a pillow, progression free survival was 11.3 months in the control arm and it wasn't reached in the triplet arm with what we have. It has a ratio of .73 so 27% decrease in that risk of progression. I think overall what we can say in terms of potential impact on patient care. This is the first study that where a triplet beats a doublet in kidney cancer. I think the most important next step is to find subsets of patients that will benefit. It's not for everyone from three drugs rather than two. And wait a bit to understand the impact on overall survival
